Joseph M. Tuscano

6.3k total citations
150 papers, 4.3k citations indexed

About

Joseph M. Tuscano is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Joseph M. Tuscano has authored 150 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pathology and Forensic Medicine, 54 papers in Oncology and 46 papers in Genetics. Recurrent topics in Joseph M. Tuscano's work include Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (45 papers) and CAR-T cell therapy research (19 papers). Joseph M. Tuscano is often cited by papers focused on Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (45 papers) and CAR-T cell therapy research (19 papers). Joseph M. Tuscano collaborates with scholars based in United States, Canada and France. Joseph M. Tuscano's co-authors include John H. Kehrl, Robert T. OʼDonnell, Thomas F. Tedder, Ted Wun, Shinichi Sato, Thomas M. Habermann, Kit S. Lam, Carol M. Richman, Dennis Pietronigro and Izidore S. Lossos and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Accounts of Chemical Research.

In The Last Decade

Joseph M. Tuscano

143 papers receiving 4.2k citations

Peers

Countries citing papers authored by Joseph M. Tuscano

Since Specialization

Citations

This map shows the geographic impact of Joseph M. Tuscano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Tuscano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Tuscano more than expected).

Fields of papers citing papers by Joseph M. Tuscano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph M. Tuscano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Tuscano. The network helps show where Joseph M. Tuscano may publish in the future.

Co-authorship network of co-authors of Joseph M. Tuscano

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph M. Tuscano. A scholar is included among the top collaborators of Joseph M. Tuscano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph M. Tuscano. Joseph M. Tuscano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis 2025 ·PubMed ·Aaron S. Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth Brém, Matthew J. Wieduwilt, Guillaume Luxardi, Paul Kaesberg, (unknown), (unknown), Joseph M. Tuscano	0
2	A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503) 2025 ·Leukemia Research ·Brian A. Jonas, (unknown), Peter Curtin, Gary J. Schiller, Deepa Jeyakumar, Dimitrios Tzachanis, Rafael Bejar, Lihong Qi, Matthew J. Wieduwilt, Joseph M. Tuscano, Lloyd E. Damon, Aaron C. Logan	0
3	A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma 2024 ·The Oncologist ·(unknown), Ajay K. Gopal, Joseph M. Tuscano, Daniel O. Persky	4
4	Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia 2024 ·Blood ·Brian A. Jonas, Zarir E. Karanjawala, (unknown), (unknown), Mehrdad Abedi, (unknown), Aaron S. Rosenberg, (unknown), Lihong Qi, Joseph M. Tuscano	1
5	Checkpoint inhibition in hematologic malignancies 2023 ·Frontiers in Oncology ·(unknown), (unknown), Joseph M. Tuscano	6
6	Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome 2023 ·Blood ·Sunmin Park, (unknown), Joseph M. Tuscano, John M. Timmerman, Caspian Oliai	1
7	A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo 2023 ·Current Issues in Molecular Biology ·(unknown), Joshua F. Meckler, Robert T. OʼDonnell, Joseph M. Tuscano	1
8	Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL) 2021 ·Blood ·Paolo Strati, Eliza A. Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy S. Chu, Mary Ann Anderson, (unknown), Michael R. Burgess, Kristen Hege, (unknown), Sarandeep S. S. Boyanapalli, (unknown), Frank Shen, Amitkumar Mehta	15
9	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients 2021 ·Blood Cancer Journal ·Aaron S. Rosenberg, Ann Brunson, Joseph M. Tuscano, Brian A. Jonas, (unknown), Ted Wun, Theresa H.M. Keegan	13
10	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), JULIAN R. DAVIS, Brian A. Jonas, Joseph M. Tuscano, Aaron S. Rosenberg, Mehrdad Abedi	3
11	A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma 2019 ·Clinical Cancer Research ·Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao‐Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, Edward M. Newman	34
12	Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis 2019 ·Blood ·Christina Poh, Paul Frankel, Christopher Ruel, Mehrdad Abedi, (unknown), Caitlin Costello, Jasmine Zain, Lihua E. Budde, Basem M. William, Francine M. Foss, Brian A. Jonas, Aaron S. Rosenberg, Edward M. Newman, Joseph M. Tuscano	25
13	Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint 2017 ·Blood ·Aaron S. Rosenberg, Thierry Façon, Safiya Abouzaid, Shankar Srinivasan, (unknown), Kejal Parikh, Joseph M. Tuscano	1
14	Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate 2016 ·Molecular Medicine ·Noriko Satake, Connie P.M. Duong, (unknown), (unknown), Cathy Chen, (unknown), Shuling Guo, Punit P. Seth, Yueju Li, Laurel Beckett, Jong Chung, Jan A. Nolta, Nitin Nitin, Joseph M. Tuscano	32
15	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) 2012 ·Journal of Clinical Oncology ·Leo I. Gordon, Fangxin Hong, Richard I. Fisher, Nancy L. Bartlett, Joseph M. Connors, Randy D. Gascoyne, Henry Wagner, Patrick J. Stiff, Bruce D. Cheson, Mary Gospodarowicz, Ranjana H. Advani, Brad S. Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph M. Tuscano, Richard T. Hoppe, Sandra J. Horning	194
16	A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia 2011 ·Leukemia ·Mark Kirschbaum, Timothy W. Synold, Anthony S. Stein, Joseph M. Tuscano, Jasmine Zain, Leslie Popplewell, Chatchada Karanes, Margaret O’Donnell, (unknown), Ana Rosa Rincón‐Sánchez, James R. Wright, Paul Frankel, Stephen J. Forman, Edward M. Newman	14
17	Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders 2009 ·Autoimmunity Reviews ·Jacob Sands, Joseph M. Tuscano	28
18	Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma 2008 ·Journal of Clinical Oncology ·Peter H. Wiernik, Izidore S. Lossos, Joseph M. Tuscano, Glen R. Justice, Julie M. Vose, Craig E. Cole, Wwt Lam, Kyle McBride, Kenton Wride, Dennis Pietronigro, Kenichi Takeshita, Annette Ervin‐Haynes, Jerome B. Zeldis, Thomas M. Habermann	300
19	Non-destructive Identification of Individual Leukemia Cells by Optical Trapping Raman Spectroscopy 2007 ·University of North Texas Digital Library (University of North Texas) ·James W. Chan, Douglas S. Taylor, Stephen M. Lane, Theodore Zwerdling, Joseph M. Tuscano, Thomas Huser	1
20	Engagement of the adhesion receptor cd22 triggers a potent stimulatory signal for b cells and blocking cd22/cd22l interactions impairs t-cell proliferation 1996 ·The FASEB Journal ·Joseph M. Tuscano, Thomas F. Tedder, John H. Kehrl	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact